1990
DOI: 10.1016/0730-725x(90)90097-l
|View full text |Cite
|
Sign up to set email alerts
|

A comparative study of manganese meso-sulfonatophenyl porphyrins: Contrast-enhancing agents for tumors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
25
0

Year Published

1991
1991
2014
2014

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 51 publications
(25 citation statements)
references
References 11 publications
0
25
0
Order By: Relevance
“…Sulphonated manganese-and iron-porphyrins have been developed in our laboratory for mimicking ligninase (Labat & Meunier, 1989) or chloroperoxidase (Labat & Meunier, 1990), and as biomimetic catalysts for the oxidation of pollutants or drugs (Bernadou et al, 1991;Vidal et al, 1993;Gaggero et al, 1994). The manganese complex of meso-tetrasulphonatophenylporphyrin (l-Mn; Table 1) has also been studied by several groups as a contrastenhancing agent for tumour imaging by nuclear magnetic resonance (NMR) imaging (Megnin et al, 1987;Fiel et al, 1990). No toxicity of l-Mn was observed to the human breast cancer cell line MCF-7 at 0.1 mg mL-l (Megnin et al,1987).…”
Section: Introductionmentioning
confidence: 99%
“…Sulphonated manganese-and iron-porphyrins have been developed in our laboratory for mimicking ligninase (Labat & Meunier, 1989) or chloroperoxidase (Labat & Meunier, 1990), and as biomimetic catalysts for the oxidation of pollutants or drugs (Bernadou et al, 1991;Vidal et al, 1993;Gaggero et al, 1994). The manganese complex of meso-tetrasulphonatophenylporphyrin (l-Mn; Table 1) has also been studied by several groups as a contrastenhancing agent for tumour imaging by nuclear magnetic resonance (NMR) imaging (Megnin et al, 1987;Fiel et al, 1990). No toxicity of l-Mn was observed to the human breast cancer cell line MCF-7 at 0.1 mg mL-l (Megnin et al,1987).…”
Section: Introductionmentioning
confidence: 99%
“…The rationales governing porphyrin-mediated cancer photodynamic therapy are based on ''tumor-localizing'' and photosensitizing properties of the agents. By analogy, the tumor ''preferential uptake'' of porphyrins has also been exploited for developing paramagnetic metalloporphyrins as ''tumor-seeking'' MRI contrast agents (Chen et al 1984;Ogan et al 1987;Furmanski and Longley 1988;Bockhorst et al 1990;Fiel et al 1990;Van Zijl et al 1990;Nelson and Schmiedl 1991;Ebert et al 1992;Place et al 1992;Hindre et al 1993;Young et al 1994;Saini et al 1995).…”
Section: 4mentioning
confidence: 97%
“…Mn-porphyrins show high stability compared to other metalloporphyrins, usually having much higher longitudinal relaxivities [20]. In addition, Mn-porphyrins are intended to be used as targeted MRI agents because of their tumorous ''preferential uptake'' property [20,21]. Compared with SPIO NPs, small molecule paramagnetic metal complexes have more advantages due to high contrast ability and easy urinary excretion [1].…”
Section: Introductionmentioning
confidence: 98%